Browsing Category
Pharma Industry News
4718 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Ipsen closes Kartos Therapeutics acquisition as $1.75bn potential bet moves into Phase III execution
Ipsen completes its Kartos Therapeutics acquisition, adding Phase III navtemadlin under a deal worth up to $1.75bn. See what comes next.
Fast Track win puts BlossomHill’s BH-30643’s 50% early response signal gets FDA Fast Track backing as BlossomHill goes public
BH-30643 wins FDA Fast Track status as BlossomHill directs $70m of its fresh IPO capital toward its EGFR-resistant lung cancer program.
Immatics skips interim anzu-cel analysis and adds 90 patients ahead of pivotal 2027 verdict
Immatics adds 90 patients to anzu-cel Phase 3 while its $448.2m liquidity backs a definitive 2027 melanoma readout and planned BLA.
Oncolytics maps accelerated approval path for pelareorep while cash drops to $4.1m
FDA feedback could speed pelareorep toward pivotal colorectal cancer testing, but Oncolytics’ $4.1m cash balance puts financing in focus.
Lupin adds Yuvezzi to €190m VISUfarma bet as European ophthalmology strategy takes shape
Lupin has secured exclusive Yuvezzi rights across major European markets through VISUfarma, extending its €190 million ophthalmology investment into a differentiated prescription therapy that still requires regional approvals.
A $50m quarter changes the stakes for UroGen as UGN-103 reaches FDA
UroGen files UGN-103 with the FDA as ZUSDURI sales surge 73%, potentially extending its fast-growing bladder cancer franchise into 2044.
Jazz Pharmaceuticals to acquire Actio Biosciences for up to $1.32bn in rare epilepsy expansion
Jazz Pharmaceuticals is committing $820 million upfront for Actio Biosciences and ABS-1230, placing a sizeable bet on a genetically targeted epilepsy therapy whose ongoing Phase 1b/2a study could potentially support a U.S. approval filing.
Fulcrum Therapeutics agrees reverse merger with Slate Medicines and $270m dividend
Fulcrum's $270m dividend and 5% stub hand Slate a Nasdaq listing, but SLTE-1009's PACAP bet must beat CGRP incumbents to justify a $350m valuation.
Mesoblast completes 350-patient Phase 3 treatment as mid-2027 back pain readout becomes next valuation test
Mesoblast has completed treatment of 350 Phase 3 back pain patients, putting rexlemestrocel-L on course for a pivotal mid-2027 efficacy readout.
PMV’s $79.4m cash pile now hinges on rezatapopt’s 2027 ovarian cancer FDA bid
PMV completes key rezatapopt enrollment with a 2027 FDA filing ahead as its $79.4m cash balance exceeds its current market value.